KYTX · Kyverna Therapeutics, Inc.
$8.61
-0.23 (-2.60%)
At close · Aug 26
Market Cap
$544.22M
Shares
61.84M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Naji H. Gehchan | Chief Medical and Development Officer | $2,085,173 |
| Warner Biddle | Chief Executive Officer | $1,814,980 |
| Marc Grasso | Chief Financial Officer | $1,663,536 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Warner Biddle | Chief Executive Officer | $14,992,896 |
| Peter Maag | Former Chief Executive Officer | $1,481,230 |
| James Chung | M.D., Ph.D. Former Chief Medical Officer | $624,576 |
| Karen Walker | Chief Technology Officer | $591,360 |
| Dominic Borie | M.D., Ph.D. Former President, Research and Development | $587,840 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| James Chung | M.D., Ph.D. Former Chief Medical Officer | $1,166,122 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Gregory Martini | Chief Financial Officer | Appointed | 2026-05-18 |
| Sravan Emany | Class I director | Appointed | 2026-02-24 |
| Andrew Miller | Class III director | Appointed | 2026-02-24 |
| Mayo Pujols | Chief Technology Officer | Appointed | 2026-02-03 |
| Karen Walker | Chief Technology Officer | Retired | 2026-02-03 |
| Christi Shaw | Executive Chairperson of the Board | Appointed | 2026-01-12 |
| Steve Liapis, Ph.D. | member of the Board and all committees thereof | Resigned | 2025-09-25 |
| Marc Grasso | Chief Financial Officer | Appointed | 2025-06-30 |
| James Chung, M.D., Ph.D. | Chief Medical Officer | Resigned | 2024-11-26 |
| James Chung, M.D., Ph.D. | Chief Medical Officer | Resigned | 2024-11-13 |
| Mert Aktar | Class III director | Appointed | 2024-10-21 |
| Warner Biddle | Class III director | Appointed | 2024-09-16 |
| Warner Biddle | Chief Executive Officer | Appointed | 2024-09-16 |
Key facts
CIK
1994702
CUSIP
501976104
13F (30d)
108 filings
107 filers
Visit website
Investor relations